Abstract
Microdialysis is a technique for sampling the chemistry of the interstitial fluid of tissues and organs in animal and man. It is minimally invasive and simple to perform in a clinical setting. Although microdialysis samples essentially all small molecular substances present in the interstitial fluid the use of microdialysis in neurointensive care has focused on markers of ischemia and cell damage. The lactate / pyruvate ratio is a well-known marker of changes in the redox state of cells caused by ischemia Glycerol is an integral component of cell membranes. Loss of energy due to ischemia eventually leads to an influx of calcium and a decomposition of cell membranes, which liberates glycerol into the interstitial fluid. Thus the lactate / pyruvate ratio and glycerol have become the most important markers of ischemia and cell membrane damage. While the primary insult at the site of the accident is beyond our control, secondary insults during intensive care should be avoided by all means. Therefore, the single most important finding from microdialysis studies is the dramatic difference in the vulnerability of the penumbra surrounding a lesion as compared to normal brain tissue allowing early detection of secondary insults after traumatic brain injury as well as the onset of vasospasm after subarachnoid hemorrhage.
Keywords: microdialysis, neurointensive care, ischemia, penumbra, traumatic brain injury
Current Pharmaceutical Design
Title: Microdialysis in Neurointensive Care
Volume: 10 Issue: 18
Author(s): Urban Ungerstedt and Elham Rostami
Affiliation:
Keywords: microdialysis, neurointensive care, ischemia, penumbra, traumatic brain injury
Abstract: Microdialysis is a technique for sampling the chemistry of the interstitial fluid of tissues and organs in animal and man. It is minimally invasive and simple to perform in a clinical setting. Although microdialysis samples essentially all small molecular substances present in the interstitial fluid the use of microdialysis in neurointensive care has focused on markers of ischemia and cell damage. The lactate / pyruvate ratio is a well-known marker of changes in the redox state of cells caused by ischemia Glycerol is an integral component of cell membranes. Loss of energy due to ischemia eventually leads to an influx of calcium and a decomposition of cell membranes, which liberates glycerol into the interstitial fluid. Thus the lactate / pyruvate ratio and glycerol have become the most important markers of ischemia and cell membrane damage. While the primary insult at the site of the accident is beyond our control, secondary insults during intensive care should be avoided by all means. Therefore, the single most important finding from microdialysis studies is the dramatic difference in the vulnerability of the penumbra surrounding a lesion as compared to normal brain tissue allowing early detection of secondary insults after traumatic brain injury as well as the onset of vasospasm after subarachnoid hemorrhage.
Export Options
About this article
Cite this article as:
Ungerstedt Urban and Rostami Elham, Microdialysis in Neurointensive Care, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384105
DOI https://dx.doi.org/10.2174/1381612043384105 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selection and Evaluation of the Pediatric Epilepsy Surgical Candidates
Current Pediatric Reviews Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Conference Report: (Annual Advances in Neurorestoratology: A Summary of IANR VI and 10th GCNN Conference, Bucharest, Romania, April 4-7, 2013)
CNS & Neurological Disorders - Drug Targets Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis
Current Drug Metabolism Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Taming the Storm in the Heart: Exploring Different Therapeutic Choices Against Myocardial Inflammation in COVID-19
Recent Advances in Anti-Infective Drug Discovery